MediWound Ltd. (NASDAQ:MDWD) Receives $31.80 Average Price Target from Brokerages

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five brokerages that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $31.80.

MDWD has been the subject of several research analyst reports. Wall Street Zen raised MediWound to a "sell" rating in a report on Friday, March 21st. Oppenheimer started coverage on MediWound in a research report on Monday, June 2nd. They issued an "outperform" rating and a $34.00 target price on the stock. HC Wainwright set a $31.00 price target on shares of MediWound and gave the company a "buy" rating in a research report on Thursday, May 22nd. Finally, Alliance Global Partners initiated coverage on shares of MediWound in a research note on Friday, May 2nd. They issued a "buy" rating and a $25.00 price objective on the stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Yelin Lapidot Holdings Management Ltd. raised its holdings in MediWound by 13.4% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company's stock valued at $15,154,000 after acquiring an additional 100,618 shares during the period. Northern Trust Corp grew its position in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock worth $2,577,000 after purchasing an additional 70,367 shares in the last quarter. Essex Investment Management Co. LLC raised its stake in MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock valued at $2,651,000 after purchasing an additional 35,012 shares during the period. MGO One Seven LLC bought a new stake in MediWound during the 4th quarter valued at approximately $216,000. Finally, Silverberg Bernstein Capital Management LLC lifted its holdings in MediWound by 13.1% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company's stock worth $1,613,000 after purchasing an additional 12,060 shares in the last quarter. Institutional investors own 46.83% of the company's stock.

MediWound Stock Up 0.6%

Shares of NASDAQ MDWD traded up $0.11 during trading on Friday, reaching $19.37. 46,749 shares of the company traded hands, compared to its average volume of 86,958. The firm has a 50 day simple moving average of $19.66 and a 200-day simple moving average of $18.25. MediWound has a 52-week low of $14.14 and a 52-week high of $24.00. The stock has a market capitalization of $209.39 million, a PE ratio of -9.27 and a beta of 0.38.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. During the same quarter in the previous year, the firm posted ($1.05) EPS. As a group, research analysts predict that MediWound will post -2.66 EPS for the current year.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.